Evidence map›Paper›PMID 41079716›Full record

ArticleFrontiers in pharmacology2025

Clozapine is responsible for the

Jian Wang, Jiale Qin, Katsushi Kumata, Ming-Rong Zhang, Jun Qian, Wen Zhou, Bin Ji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jian WangDepartment of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jiale QinDepartment of Radiopharmacy and Molecular Imaging, Minhang Hospital and School of Pharmaceutical Sciences, Fudan University, Shanghai, China.
Katsushi KumataDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Jun QianDepartment of Radiopharmacy and Molecular Imaging, Minhang Hospital and School of Pharmaceutical Sciences, Fudan University, Shanghai, China.
Wen ZhouTianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China.
Bin JiDepartment of Radiopharmacy and Molecular Imaging, Minhang Hospital and School of Pharmaceutical Sciences, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although clozapine-N-oxide (CNO), a major metabolite of clozapine (CLZ), is a widely used agonist of designer receptors exclusively activated by designer drugs (DREADDs), the compound responsible for visualizing or activating DREADDs in nuclear medicine imaging and at pharmacological doses in murine models remains unclear. In this study, we performed positron emission tomography (PET) imaging and

Indexed as

clozapineclozapine-N-oxidedesigner receptors exclusively activated by designer drugsex vivo autoradiographyhuman M4 mAChR DREADDs

Identifiers

PMID41079716
PMCPMC12507898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.